Opening the book…
Regulatory submissions provide information required by an agency for a defined purpose. An investigational new drug application (IND), for example, contains relevant nonclinical, manufacturing, and clinical information for a proposed human investigation. An effective IND is not marketing approval, and applicable IRB and participant-protection requirements must also be met.
Before batch release, the authorized quality unit reviews appropriate production and control records, including packaging and labeling records, to determine whether established requirements have been met. Relevant discrepancies and failures must be investigated. The quality unit’s approval or rejection authority is described in 21 CFR 211.22; production record review is addressed in 211.192.
Production, laboratory, and other staff may review records within their responsibilities. Regulations do not prescribe a universal sequence involving three directors followed by an independent Regulatory Affairs Director. The company must define qualified roles and adequate authority for its operations.
A release authorization records the batch, disposition, approving person, date, and relevant conditions or references. A certificate of analysis (CoA) generally reports specified tests and results. A certificate of conformity or release certificate may state conformity or release status. Their names and content vary, and a CoA is not automatically a substitute for the required release decision.
Packaging authorization must identify its scope. Approval to package or repackage a product does not itself authorize final shipment. Follow the applicable release process and investigate relevant complaints through the assigned quality system responsibilities.
This page titled 13.16: Regulatory Submissions and Product Release was last modified on Sat, 31 Oct 2026 16:45:09 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.